Differential expression of human equilibrative nucleoside transporter 1 (hENT1) protein in the Reed-Sternberg cells of Hodgkin's disease

Leukemia and Lymphoma

Volumn 43, Issue 7, 2002, Pages 1435-1440

  Reiman, Tony ^a   Clarke, Marilyn L ^a   Dabbagh, Laith ^a   Vsianska, Michaela ^b   Coupland, Robert W ^e   Belch, Andrew R ^a   Baldwin, Stephen A ^c   Young, James D ^d   Cass, Carol E ^e   Mackey, John R ^e  

^a CROSS CANCER INSTITUTE   (Canada)

^b MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d UNIVERSITY OF ALBERTA   (Canada)

^e NONE

Author keywords

Drug resistance; Gemcitabine; hENT1; Hodgkin's disease; Immunohistochemistry; Nucleoside transport

Indexed keywords

CARRIER PROTEIN; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GEMCITABINE; MONOCLONAL ANTIBODY; NUCLEOSIDE ANALOG; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VIRUS RNA; SLC29A1 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGE; CANCER RECURRENCE; CANCER STAGING; CELL MEMBRANE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG USE; EPSTEIN BARR VIRUS; FEMALE; FROZEN SECTION; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; HYDROPHILICITY; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MALE; NUCLEOSIDE TRANSPORT; PREDICTION; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RATING SCALE; REED STERNBERG CELL; REVIEW; SCORING SYSTEM; TARGET CELL; AGE DISTRIBUTION; AGED; ARTICLE; CHEMISTRY; GENE EXPRESSION REGULATION; METABOLISM; METHODOLOGY; MIDDLE AGED; MORTALITY; NONPARAMETRIC TEST; PATHOLOGY; STAINING; STANDARD; VIRUS INFECTION;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CHILD; EPSTEIN-BARR VIRUS INFECTIONS; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; MALE; MIDDLE AGED; REED-STERNBERG CELLS; STAINING AND LABELING; STATISTICS, NONPARAMETRIC;

EID: 85047685004     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819022386725     Document Type: Review

References (51)

1. "Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients"
2. "Gemcitabine in the treatment of refractory Hodgkin's disease: Results of a multicenter phase II study"
3. "Phase I studies with the novel nucleoside analog gemcitabine"
4. "Gemcitabine: Metabolism, mechanisms of action, and self-potentiation"
5. "Nucleoside transporter proteins: Emerging targets for drug discovery"
6. "Nucleoside transporters of mammalian cells"
7. "Nucleoside transporters: Molecular biology and implications for therapeutic development"
8. "The role of nucleoside transport in anticancer drug resistance"
9. "Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines"
10. "Gemcitabine membrane transport capabilities of normal human hematopoietic progenitor (CD34 +) cells"
11. "Immunohistochemical variation of human equilibrative nucleoside transporter 1 (hENT1) protein in primary breast cancers"
12. "Combination therapy of mouse leukemia L1210 by 1-beta-D-arabinofuranosylcytosine and 6-[(4-nitrobenzyl)thio]-9-beta-D-ribofuranosylpurine"
13. "Absence of binding sites for the transport inhibitor nitrobenzylthioinosine on nucleoside transport-deficient mouse lymphoma cells"
14. "A comparison of the abilities of nitrobenzylthioinosine, dilazep, and dipyridamole to protect human hematopoietic cells from 7-deazaadenosine (tubercidin)"
15. "Low specificity of the nucleoside transport mechanism of RPMI 6410 cells"
16. "Cytosine arabinoside transport by human leukaemic cells"
17. "Cytosine arabinoside influx and nucleoside transport sites in acute leukemia"
18. "Es nucleoside transporter content of acute leukemia cells: Role in cell sensitivity to cytarabine (arac)"
19. "Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein"
20. "Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma"
21. "Distinct regional distribution of human equilibrative nucleoside transporter proteins 1 and 2 (hENT1 and hENT2) in the central nervous system"
22. "Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting"
23. "Effect of Epstein-Barr virus infection on response to chemotherapy and survival in Hodgkin's disease"
24. "Epidemiology of EBV and Hodgkin's lymphoma"
25. "Phase II study with gemcitabine in pretreated patients with Hodgkin's (HD) and non-Hodgkin's lymphomas (NHL): Results of a multicenter study"
26. "Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma"
27. "High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias"
28. "Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease"
29. "Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease"
30. "Hodgkin's disease. Chapter 45.6"
31. "Phase II study of cytarabine in Hodgkin's disease
32. "Transport of 2′-deoxycoformycin in human leukemic and lymphoma cells"
33. "Selective protection of tubercidin toxicity by nitrobenzyl thioinosine in normal tissues but not in human neuroblastoma cells"
34. "Expression of high levels of nitrobenzylthioinosine-sensitive nucleoside transport in cultured human choriocarcinoma (BeWo) cells"
35. "Modulation of the equilibrative nucleoside transporter by inhibitors of DNA synthesis"
36. "Fluctuations in nucleoside uptake and binding of the inhibitor of nucleoside transport, nitrobenzylthioinosine, during the replication cycle of HeLa cells"
37. "Assessment of proliferative responses to granulocyte-macrophage colony-stimulating factor (GM-CSF) in acute myeloid leukaemia using a fluorescent ligand for the nucleoside transporter"
38. "Nucleoside transport and proliferative rate in human thymocytes and lymphocytes"
39. "Nitrobenzylthioinosine-binding protein overexpression in human breast, liver, stomach and colorectal tumour tissues"
40. "A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy"
41. "Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma"
42. "Fatal pulmonary toxicity resulting from treatment with gemcitabine"
43. "Effects of gemcitabine on renal function in patients with non-small cell lung cancer"
44. "Membranoproliferative glomerulonephritis following gemcitabine and vinorelbine chemotherapy for peritoneal mesothelioma"
45. "Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms"
46. "Single-cell analysis of Hodgkin and Reed-Sternberg cells: Molecular heterogeneity of gene expression and p53 mutations"
47. "Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development"
48. "Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells"
49. "Detection of identical Hodgkin-Reed-Sternberg cell specific immunoglobulin gene rearrangements in a patient with Hodgkin's disease of mixed cellularity subtype at primary diagnosis and in relapse two and a half years later"
50. "A prognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced Hodgkin's disease"